India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
This article was originally published in PharmAsia News
Executive Summary
India's National Pharmaceutical Pricing Authority has imposed a 15-day deadline on 11 drug manufacturers to rein in costs of certain drugs, citing the "public interest" of lower prices for consumers
You may also be interested in...
IP Protection Concerns Grow In India, PhRMA Says
Intellectual property protection in India is an increasing concern for industry following a year of regulatory action and inaction, according to the Pharmaceutical Research and Manufacturers of America
IP Protection Concerns Grow In India, PhRMA Says
Intellectual property protection in India is an increasing concern for industry following a year of regulatory action and inaction, according to the Pharmaceutical Research and Manufacturers of America
Indian Court Hands Novartis Setback In Gleevec Patent Case
Novartis says decision will have innovation, intellectual property repercussions for other pharma firms operating in India.